![]() 1 The aim of this study was to elucidate the mechanism of action of baricitinib in SLE. ![]() Background/Purpose: Baricitinib, a Janus kinase (JAK)1/JAK2 inhibitor, improved disease activity in systemic lupus erythematosus (SLE) adults receiving standard background therapy in a phase 2 trial (NCT02708095). ![]()
0 Comments
Leave a Reply. |